Tanshinone IIA Protects against Dextran Sulfate Sodium- (DSS-)‎ Induced Colitis in Mice by Modulation of Neutrophil Infiltration and Activation

Abstract EN

Neutrophils play a critical role in the initiation and maintenance of intestinal inflammation.

However, conventional neutrophil-targeted therapies can impair normal host defense.

Tanshinone IIA has been recently revealed to act directly on neutrophils.

Hence, we aimed at investigating whether Tanshinone IIA can protect against experimental colitis through modulation of neutrophils.

We induced colitis in C57BL/6 mice by giving 3% dextran sulfate sodium (DSS) orally, and meanwhile, we treated mice daily with Tanshinone IIA intraperitoneally.

The severity of colitis was evaluated by calculating disease activity index (DAI) and histological parameters.

Neutrophil infiltration and activation in the colons of mice were measured.

Moreover, whether Tanshinone IIA has direct effects on neutrophil migration and activation was determined in vitro.

Our data showed that Tanshinone IIA significantly ameliorated the severity of DSS-induced colitis in mice, evidenced by the reduced DAI and improved colonic inflammation.

In addition, Tanshinone IIA decreased neutrophil infiltration of intestinal mucosa and activation and reduced colonic inflammatory cytokines in DSS-treated mice.

Furthermore, Tanshinone IIA was demonstrated to significantly suppress neutrophil migration and activation.

These results provide compelling evidence that Tanshinone IIA has a therapeutic potential for alleviating inflammatory colitis in mice, which is possibly mediated by the immunomodulation of neutrophils.